


## Catalog # 10-2141 GDC-0941

CAS# 957054-30-7

Pictilisib; 4-[2-(1*H*-Indazol-4-yl)-6-[(4-methylsulfonylpiperazin-1-yl)methyl]thieno[3,2-*d*]pyrimidin-4-yl]morpholine Lot # FBS2148



GDC-0941 is a potent and selective inhibitor of class I phosphatidylinositol-3-kinases (PI3K) with significant antitumor activity –  $IC_{50}$ 's: PI3K $\alpha$  = 3nM, PI3K $\beta$  = 33 nM, PI3K $\delta$  = 3 nM, PI3K $\gamma$  = 75 nM.<sup>1,2</sup> GDC-0941 is the chemical probe of choice for the pan-inhibition of class I PI3K's.<sup>3</sup> Currently in clinical trials.<sup>4</sup>

- Folkes et al. (2008), The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4morpholin-4-yl-thieno[3,2-d]pyrimidine(GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer, J.Med.Chem. 51 5522
- 2) Raynaud et al. (2009), Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinase: from PI-103 through PI-540, PI620 to the oral agent GDC-0941; Mol.Cancer Ther. **8** 1725
- 3) Knapp et al. (2013), A public-private partnership to unlock the untargeted kinome; Nat.Chem.Biol. 9 3
- 4) Sarker et al. (2015), First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors; Clin.Cancer Res. **21** 77

## PHYSICAL DATA

Molecular Weight:	513.64
Molecular Formula:	C <sub>23</sub> H <sub>27</sub> N <sub>7</sub> O <sub>3</sub> S <sub>2</sub>
Purity:	99% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (>25 mg/mL)
Physical Description:	White or off-white solid
Storage and Stability:	Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in
	DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.